{"success":true,"data":{"pressRelease":{"id":"173374","rtpr_id":"nWkr95Fr2F-20261020","ticker":"MBPH","exchange":"Nasdaq Stockholm","all_tickers":["MBPH"],"title":"Moberg Pharma's Nomination Committee appointed","author":"Cision","published_at":"2026-10-20T06:00:12.441Z","article_body":"Moberg Pharma\nSTOCKHOLM, October 20(th), 2026 - In accordance with the resolution of the\nAnnual General Meeting on May 21(st), 2026, the Chairman of the Board has\ncontacted the company's two largest shareholders or group of shareholders in\nterms of votes to form a Nomination Committee. These shareholders have been\ninvited to appoint one representative each who, together with the Chairman of\nthe Board, will comprise the Nomination Committee. As not all of the company's\ntwo largest shareholders or group of shareholders have wished to appoint such\nrepresentative, the third largest shareholder/group of shareholders have been\ninvited to appoint one representative and so on until the Nomination Committee\nnow comprises of three members, in accordance with the resolution of the\nAnnual General Meeting on May 21(st), 2026.\n\nMoberg Pharma’s Nomination Committee ahead of the Annual General Meeting for\nthe fiscal year January – December 2026 comprises:\n* Pedro Noronha, appointed by Noster Capital\n* Eddie Jalmestam, appointed by Richard Ding\n* Lars Johansson, Chairman of the Board\nTogether, the Nomination Committee represents 10,7 percent of the shares in\nMoberg Pharma as of September 30(th), 2025.\n\nThe Nomination Committee shall submit proposals for the fiscal year January\n– December 2026 by the Annual General Meeting pertaining to the election of\nChairman of the Board, fees and composition of the Board, auditors’ fees and\nthe election of auditors.\n\nThe Annual General Meeting for the fiscal year January – December 2026 will\nbe held on May 20(th), 2027.\n\nShareholders wishing to submit proposals to Moberg Pharma’s Nomination\nCommittee can do so by e-mail to info@mobergpharma.se by April 1(st), 2027.\n\nFor additional information, please contact:\nAnna Ljung, CEO, Phone: +46 8 522 307 01, e-mail:\nanna.ljung@mobergpharma.se\n\nAbout this information\nThe information was released for public distribution through the contact named\nabove, on October 20(th), 2026, at 8:00 am CET.\n\nAbout Moberg Pharma, www.mobergpharma.com \nMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on\ncommercializing proprietary innovations based on drug delivery of proven\ncompounds. The company's drug MOB-015 is a novel topical treatment for\nonychomycosis (nail fungus) with market approval in 14 countries. Phase 3\nclinical trials for MOB-015 involving more than 800 patients indicate that the\nproduct has the potential to become the future market leader in onychomycosis.\nMOB-015 is sold in Sweden, Norway and Israel under the brand name\nTerclara(®). Moberg Pharma has agreements with commercial partners in place\nin various regions including Europe, APAC, Canada and China. Moberg Pharma is\nheadquartered in Stockholm and the company's shares are listed under Small Cap\non Nasdaq Stockholm (OMX: MOB).\n\nhttps://news.cision.com/moberg-pharma/r/moberg-pharma-s-nomination-committee-appointed%2Cc4412087\n\nhttps://mb.cision.com/Main/1662/4412087/4326391.pdf\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr95Fr2F-20261020","title":"Moberg Pharma's Nomination Committee appointed","author":"Cision","ticker":"MBPH","created":"2026-10-20T06:00:12.441Z","tickers":["MBPH"],"exchange":"Nasdaq Stockholm","article_body":"Moberg Pharma\nSTOCKHOLM, October 20(th), 2026 - In accordance with the resolution of the\nAnnual General Meeting on May 21(st), 2026, the Chairman of the Board has\ncontacted the company's two largest shareholders or group of shareholders in\nterms of votes to form a Nomination Committee. These shareholders have been\ninvited to appoint one representative each who, together with the Chairman of\nthe Board, will comprise the Nomination Committee. As not all of the company's\ntwo largest shareholders or group of shareholders have wished to appoint such\nrepresentative, the third largest shareholder/group of shareholders have been\ninvited to appoint one representative and so on until the Nomination Committee\nnow comprises of three members, in accordance with the resolution of the\nAnnual General Meeting on May 21(st), 2026.\n\nMoberg Pharma’s Nomination Committee ahead of the Annual General Meeting for\nthe fiscal year January – December 2026 comprises:\n* Pedro Noronha, appointed by Noster Capital\n* Eddie Jalmestam, appointed by Richard Ding\n* Lars Johansson, Chairman of the Board\nTogether, the Nomination Committee represents 10,7 percent of the shares in\nMoberg Pharma as of September 30(th), 2025.\n\nThe Nomination Committee shall submit proposals for the fiscal year January\n– December 2026 by the Annual General Meeting pertaining to the election of\nChairman of the Board, fees and composition of the Board, auditors’ fees and\nthe election of auditors.\n\nThe Annual General Meeting for the fiscal year January – December 2026 will\nbe held on May 20(th), 2027.\n\nShareholders wishing to submit proposals to Moberg Pharma’s Nomination\nCommittee can do so by e-mail to info@mobergpharma.se by April 1(st), 2027.\n\nFor additional information, please contact:\nAnna Ljung, CEO, Phone: +46 8 522 307 01, e-mail:\nanna.ljung@mobergpharma.se\n\nAbout this information\nThe information was released for public distribution through the contact named\nabove, on October 20(th), 2026, at 8:00 am CET.\n\nAbout Moberg Pharma, www.mobergpharma.com \nMoberg Pharma AB (publ) is a Swedish pharmaceutical company focused on\ncommercializing proprietary innovations based on drug delivery of proven\ncompounds. The company's drug MOB-015 is a novel topical treatment for\nonychomycosis (nail fungus) with market approval in 14 countries. Phase 3\nclinical trials for MOB-015 involving more than 800 patients indicate that the\nproduct has the potential to become the future market leader in onychomycosis.\nMOB-015 is sold in Sweden, Norway and Israel under the brand name\nTerclara(®). Moberg Pharma has agreements with commercial partners in place\nin various regions including Europe, APAC, Canada and China. Moberg Pharma is\nheadquartered in Stockholm and the company's shares are listed under Small Cap\non Nasdaq Stockholm (OMX: MOB).\n\nhttps://news.cision.com/moberg-pharma/r/moberg-pharma-s-nomination-committee-appointed%2Cc4412087\n\nhttps://mb.cision.com/Main/1662/4412087/4326391.pdf\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-10-20T06:00:12.529860948Z","server_sent_at_ms":1792476012529},"received_at":"2026-10-20T06:00:12.581Z","source_url":"https://news.cision.com/moberg-pharma/r/moberg-pharma-s-nomination-committee-appointed%2Cc4412087"},"analysis":{"id":"161468","press_release_id":"173374","analysis_json":{"industry":{"label":"Pharmaceuticals","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Moberg Pharma has appointed its Nomination Committee for the fiscal year 2026, comprising Pedro Noronha (Noster Capital), Eddie Jalmestam (Richard Ding), and Board Chairman Lars Johansson.\n\nThe committee represents 10.7% of shares as of September 30, 2025 and will propose Board composition, fees, and auditor elections ahead of the AGM on May 20, 2027.\n\nThis is routine Swedish governance-process disclosure with no operational or financial implications; the release also notes lead drug MOB-015 is approved in 14 countries and sold as Terclara in Sweden, Norway, and Israel.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine nomination committee appointment -- suppress."},"keyFigures":{"customDimensions":{"nomination_committee_shareholding":"10.7%"}},"namedEntities":{"people":[{"name":"Pedro Noronha","role":"Nomination Committee member (Noster Capital representative)"},{"name":"Eddie Jalmestam","role":"Nomination Committee member (Richard Ding representative)"},{"name":"Lars Johansson","role":"Chairman of the Board, Nomination Committee member"},{"name":"Anna Ljung","role":"CEO"}],"products":["MOB-015","Terclara"],"companies":[{"name":"Moberg Pharma AB","ticker":"MOB","relationship":"filer"},{"name":"Noster Capital","relationship":"shareholder"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine corporate-governance boilerplate: annual appointment of the Nomination Committee per AGM procedure. No change in control, strategy, or operations."},"tickerRelevance":{"others":[{"ticker":"MOB","relevance":"Nasdaq Stockholm listing of the same issuer"}],"primary":"MBPH"},"globalImportance":8,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-foreign-listing","eventGravity":"routine-governance","issuerAuthored":true}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Moberg Pharma has appointed its Nomination Committee for the fiscal year 2026, comprising Pedro Noronha (Noster Capital), Eddie Jalmestam (Richard Ding), and Board Chairman Lars Johansson.\n\nThe committee represents 10.7% of shares as of September 30, 2025 and will propose Board composition, fees, and auditor elections ahead of the AGM on May 20, 2027.\n\nThis is routine Swedish governance-process disclosure with no operational or financial implications; the release also notes lead drug MOB-015 is approved in 14 countries and sold as Terclara in Sweden, Norway, and Israel.","key_figures":{"customDimensions":{"nomination_committee_shareholding":"10.7%"}},"named_entities":{"people":[{"name":"Pedro Noronha","role":"Nomination Committee member (Noster Capital representative)"},{"name":"Eddie Jalmestam","role":"Nomination Committee member (Richard Ding representative)"},{"name":"Lars Johansson","role":"Chairman of the Board, Nomination Committee member"},{"name":"Anna Ljung","role":"CEO"}],"products":["MOB-015","Terclara"],"companies":[{"name":"Moberg Pharma AB","ticker":"MOB","relationship":"filer"},{"name":"Noster Capital","relationship":"shareholder"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-20T06:00:17.721Z","global_importance":8,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap-foreign-listing","eventGravity":"routine-governance","issuerAuthored":true}},"durationMs":5117,"modelName":"glm-5.3-flashx"}}